(VIANEWS) – Shares of BIOCARTIS (BEL 20: BCART.BR) dropped by a staggering 31.41% in 21 sessions from €0.55 to €0.38 at 11:08 EST on Friday, after five sequential sessions in a row of gains. BEL 20 is sliding 0.02% to €3,494.90, after two successive sessions in a row of losses.
About BIOCARTIS
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
Earnings Per Share
As for profitability, BIOCARTIS has a trailing twelve months EPS of €-1.04.
Volume
Today’s last reported volume for BIOCARTIS is 13302 which is 76.78% below its average volume of 195816.
More news about BIOCARTIS (BCART.BR).
